Titre:
  • Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Auteur:Deuffic-Burban, Sylvie; Schwarzinger, Michael; Obach, Dorothée; Mallet, Vincent; Pol, Stanislas; Pageaux, Georges-Philippe; Canva, Valérie; Deltenre, Pierre; Roudot-Thoraval, Françoise; Larrey, Dominique; Dhumeaux, Daniel; Mathurin, Philippe; Yazdanpanah, Yazdan
Informations sur la publication:Journal of hepatology, 61, 1, page (7-14)
Statut de publication:Publié, 2014-07
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Boceprevir
Chronic hepatitis C
Cost-effectiveness analysis
Direct-acting antivirals
Genotype 1
Interferon-free regimens
Model-based analysis
Telaprevir
Treatment initiation
MeSH keywords:Antiviral Agents -- administration & dosage -- economics
Cost-Benefit Analysis
Decision Support Techniques
Drug Therapy, Combination -- economics
France
Genotype
Hepacivirus -- drug effects -- genetics
Hepatitis C, Chronic -- drug therapy -- economics -- virology
Humans
Interferons -- administration & dosage -- economics -- therapeutic use
Liver Cirrhosis -- drug therapy -- economics -- virology
Middle Aged
Models, Economic
Oligopeptides -- administration & dosage -- economics
Proline -- administration & dosage -- analogs & derivatives -- economics
Quality-Adjusted Life Years
Ribavirin -- administration & dosage -- economics
Treatment Outcome
Langue:Anglais
Identificateurs:urn:issn:0168-8278
info:doi/10.1016/j.jhep.2014.03.011
info:pii/S0168-8278(14)00155-X
info:pmid/24650691